Abraxane News and Research

RSS

The U.S. Food and Drug Administration approved Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer.

7 Jan 2014

New research assesses nanomedicine-based approaches for treating cancer

As cancer maintains its standing as the second leading cause of death in the U.S., researchers have continued their quest for safer and more effective treatments. Among the most promising advances has been the rise of nanomedicine, the application of tiny materials and devices whose sizes are measured in the billionths of a meter to detect, diagnose and treat disease.

20 Dec 2013

Romidepsin drug shows surprising benefit in preclinical studies of inflammatory breast cancer

A drug now used to treat a type of lymphoma has shown surprising benefit in preclinical studies of inflammatory breast cancer, according to a researcher at Thomas Jefferson University's Kimmel Cancer Center.

11 Dec 2013

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Medicines Agency's: Committee for Medicinal Products for Human Use has adopted a positive opinion for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.

25 Nov 2013

NTU establishes new $60 million research institute in Nanomedicine

Nanyang Technological University is giving the development of nanotechnology a big boost, by establishing a new $60 million research institute in Nanomedicine, which focuses on the medical application of nanotechnology. An emerging field in drugs, nanomedicine are made up of tiny nano-sized particles thousands of times smaller than a grain of sand.

5 Nov 2013

NEJM publishes Celgene’s Abraxane phase III study results

Published today in the New England Journal of Medicine, a phase III clinical trial of Abraxane (paclitaxel formulated as albumin-bound nanoparticles) in combination with gemcitabine in treatment-naive patients with metastatic pancreatic cancer demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone [(median of 8.5 vs. 6.7 months) (HR 0.72, P=0.000015)].

17 Oct 2013

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation , today announced the results of the MPACT phase III clinical trial of ABRAXANE® in combination with gemcitabine were published online in the October 16th edition of the New England Journal of Medicine.

17 Oct 2013

FDA approves ABRAXANE chemotherapy drug for treatment of metastatic pancreatic cancer

The Pancreatic Cancer Action Network is pleased to announce that today ABRAXANE® was approved by the U.S. Food and Drug Administration (FDA) to treat metastatic pancreatic cancer.

7 Sep 2013

FDA approves use of abraxane to treat patients with late-stage pancreatic cancer

The U.S. Food and Drug Administration today expanded the approved uses of Abraxane (paclitaxel protein-bound particles for injectable suspension, ablumin-bound) to treat patients with late-stage (metastatic) pancreatic cancer.

7 Sep 2013

Abraxane drug gets FDA approval for patients with advanced pancreatic cancer

The U.S. Food and Drug Administration today approved Abraxane for patients with advanced pancreatic cancer, following 7 years of rigorous clinical trials overseen by Scottsdale Healthcare and the Translational Genomics Research Institute.

7 Sep 2013

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

Sorrento Therapeutics, Inc. and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq) and IG-004 (TOCOSOL paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine and the European Technology Platform on Nanomedicine in Basel, Switzerland on June 23 - 26.

21 Jun 2013

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.

23 May 2013

Protein tumor necrosis factor-alpha is a powerful weapon to control cancer

The protein tumor necrosis factor-alpha (TNF-alpha) is a powerful weapon in the arsenal to control cancer. Unfortunately, as is the case with many potent cancer therapies, the use of TNF-alpha as an anti-cancer therapy has been severely limited.

8 May 2013

TGen receives donation from Seena Magowitz Foundation for pancreatic cancer research

The Seena Magowitz Foundation has donated $500,000 from two charity golf tournaments dedicated to supporting pancreatic cancer research at the Translational Genomics Research Institute.

24 Apr 2013

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today summarized new data highlighting the progress of OncoMed's pipeline of anti-cancer biologics presented this week in an oral presentation and five posters at the Annual Meeting of the American Association of Cancer Research in Washington, DC.

11 Apr 2013

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its analysis of proprietary late clinical stage NBN-Pac formulations, namely IG-001 (Cynviloq) and IG-004 (a D-a-tocopheryl polyethylene glycol succinate (TPGS)-based paclitaxel formulation) at the annual Nanomedicine 2013 meeting in Barcelona, Spain (April 11th - 12th).

8 Apr 2013

IGDRASOL to present updates on Cynviloq at AACR annual meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its development of Cynviloq (IG-001) at the annual meeting of the American Association for Cancer Research in Washington, DC (April 6th to 10th).

1 Apr 2013

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

Australian biopharmaceutical company Specialised Therapeutics Australia announces that a phase III clinical trial of world leading breast cancer drug ABRAXANE (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival times, with double the number of patients surviving two years.

23 Jan 2013

Combination of Abraxane and gemcitabine improves survival of patients with pancreatic cancer

A new cancer drug combination demonstrated significant improvement in overall survival of late-stage pancreatic cancer patients compared to those receiving standard treatment, according to results of a Phase III clinical trial led by physicians from Scottsdale Healthcare's Virginia G. Cancer Center Clinical Trials, a partnership with the Translational Genomics Research Institute (TGen).

17 Nov 2012

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

15 Oct 2012

Abraxane News and Research

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

New research assesses nanomedicine-based approaches for treating cancer

Romidepsin drug shows surprising benefit in preclinical studies of inflammatory breast cancer

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

NTU establishes new $60 million research institute in Nanomedicine

NEJM publishes Celgene’s Abraxane phase III study results

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

FDA approves ABRAXANE chemotherapy drug for treatment of metastatic pancreatic cancer

FDA approves use of abraxane to treat patients with late-stage pancreatic cancer

Abraxane drug gets FDA approval for patients with advanced pancreatic cancer

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

Protein tumor necrosis factor-alpha is a powerful weapon to control cancer

TGen receives donation from Seena Magowitz Foundation for pancreatic cancer research

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

IGDRASOL to present updates on Cynviloq at AACR annual meeting

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

Combination of Abraxane and gemcitabine improves survival of patients with pancreatic cancer

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News